Ask My Investor AI
Public company · Frankfurt Stock Exchange (Deutsche Boerse Xetra)Published company research
BAYN

Identity verified against the Deutsche Boerse (Xetra) equity page - ISIN DE000BAY0017, WKN BAY001, symbol BAYN, Xetra Frankfurt - and Bayer's official FY2025 Annual Report (EUR reporting, Leverkusen/Germany, divisions Pharmaceuticals/Crop Science/Consumer Health). Seed ticker 'BAYN.DE' corrected to exchange symbol 'BAYN' ('.DE' is a data-vendor venue suffix, not the exchange ticker). CIK set null because Bayer deregistered from the SEC (Rule 12h-6, effective Dec 28, 2007) and no longer files periodic issuer reports; it trades in the US only as a Level 1 ADR (BAYRY, OTC) under Rule 12g3-2(b), so its financials are German public disclosures, not SEC filings. A dormant historical registrant CIK 1144145 exists from the pre-2007 20-F era; SEC endpoints returned HTTP 403 this session, so that status rests on SEC EDGAR archive references surfaced in search.

Bayer Aktiengesellschaft

Bayer is a diversified life-science group (Pharmaceuticals, Crop Science, Consumer Health) that generated FY2025 Group net sales of EUR 45,575m and operating cash flow of EUR 5,930m, with underlying earnings power (core EPS from continuing operations EUR 4.91) masked at the IFRS level by an operating loss (EBIT EUR -1,077m) and a net loss (EUR -3,620m) driven mainly by litigation provisions and impairments. The women's-health theme is captured through a disclosed, double-digit-growing contraception franchise (Mirena family EUR 1,366m, YAZ family EUR 700m) now extended into non-hormonal menopause care via Lynkuet (elinzanetant), first approved in the UK (July 2025) and by the US FDA (October 2025). The equity narrative is dominated by glyphosate/Roundup litigation and EUR 29,843m of net financial debt rather than by women's health, which is a medium-weight, diversified contributor.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
public
Ticker
BAYN
Exchange
Frankfurt Stock Exchange (Deutsche Boerse Xetra)
HQ
Germany
Currency
EUR
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

Bayer is a global top-tier pharmaceutical company and, following the 2018 Monsanto acquisition, the world's largest agricultural-inputs (Crop Science) business, with durable Consumer Health OTC brands (e.g., Aspirin, Aleve). In women's health specifically it is a long-standing leader in hormonal contraception - the Mirena/Kyleena/Jaydess levonorgestrel intrauterine systems and the YAZ/Yasmin combined oral contraceptives - and is now first-in-class in non-hormonal menopause therapy with Lynkuet (elinzanetant), the first-and-only dual NK1/NK3 receptor antagonist. Lynkuet is differentiated from Astellas' NK3-only Veozah, which carries an FDA black-box liver-injury warning and has under-performed commercially, giving Bayer a clinical and safety-positioning edge in the emerging vasomotor-symptom (VMS) category.

Scarce assets

Patent-protected molecules and a first-in-class pipeline (the elinzanetant/Lynkuet dual NK1/NK3 antagonist for menopausal VMS, backed by the OASIS phase 3 program, plus oncology and cardiorenal specialty products such as Nubeqa and Kerendia); the entrenched Mirena LNG-IUS franchise with established prescriber relationships, brand equity and manufacturing scale; Monsanto-derived germplasm and seed-trait IP with global agricultural distribution; a leading radiology contrast-media business; and iconic self-care brands. Regulatory approvals across major jurisdictions themselves act as scarce, hard-to-replicate assets in the contraception and menopause categories.

Products, segments, and customers

FY2025 Group net sales EUR 45,575m across three divisions: Pharmaceuticals (EUR 17,829m), Crop Science and Consumer Health. Pharmaceuticals growth in FY2025 came from Nubeqa, Kerendia, the Radiology business and the Mirena family, partly offset by declines in Xarelto and Eylea. Disclosed women's-healthcare product families: the Mirena family (IUS contraceptives) at EUR 1,366m (+12.5% currency/portfolio-adjusted, US-volume led) and the YAZ family (oral contraceptives) at EUR 700m (+10.7%, gains in China). Operations are global (US, EU, China and rest of world); the group reports in euros.

Theme capture

Bayer captures the 'women's health formalization' theme on two fronts: (1) an installed hormonal-contraception franchise generating disclosed, double-digit-growing revenue (Mirena family EUR 1,366m; YAZ family EUR 700m in FY2025); and (2) category expansion into non-hormonal menopause care via Lynkuet (elinzanetant) - first worldwide approval in the UK on July 10, 2025 and US FDA approval on October 24, 2025 (US launch November 2025 at ~USD 625 wholesale acquisition cost per 30-day supply), with the EU and other markets under regulatory review. A Bayer executive framed the UK approval as reflecting the company's 'longstanding commitment to advance women's health.' This formalizes menopause VMS as a distinct, reimbursable therapeutic and commercial franchise beyond contraception, though it remains a modest, diversified share of a EUR 45.6bn group.

Conditions

What must be true

  1. Lynkuet/elinzanetant must achieve meaningful commercial uptake in menopause VMS and out-execute Astellas' Veozah, building a new franchise materially larger than today's contraception base.
  2. The Mirena/contraception franchise must sustain volume-led growth (especially US) to offset pricing, reimbursement and generic/competitive pressure.
  3. The broader pharma pipeline (Nubeqa, Kerendia) must continue offsetting Xarelto loss of exclusivity and Eylea biosimilar erosion so women's health remains a funded strategic priority.
  4. Glyphosate/Roundup and PCB litigation and leverage (net financial debt EUR 29,843m) must stay contained enough that Bayer does not divest or under-invest in the women's-health/pharma platform.

Identifiable catalysts

  • US commercial launch ramp of Lynkuet (from November 2025) and additional ex-US regulatory approvals - notably the pending EU/EMA decision - with reimbursement outcomes for elinzanetant.
  • Continued double-digit growth of the Mirena product family disclosed in Bayer's quarterly/annual reporting.
  • Potential additional indications or label expansions for elinzanetant beyond the initial menopause-VMS approval.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Women's-health therapeutics developer and marketer - prescription contraception (levonorgestrel intrauterine systems and combined oral contraceptives) and a first-in-class non-hormonal menopause vasomotor-symptom therapy (Lynkuet/elinzanetant).

Women's health formalization

Medium and diversified, consistent with the seed hypothesis. Women's health is a real, issuer-disclosed and growing franchise but a modest slice of a EUR 45,575m group: named women's-healthcare product families total roughly EUR 2.07bn (Mirena EUR 1,366m + YAZ EUR 700m) - about 12% of Pharmaceuticals sales (EUR 17,829m) and ~4.5% of Group sales - now extended by the Lynkuet menopause launch. The exposure is unambiguous in therapeutic terms but not a core group earnings driver.

Evidence
Bayer's FY2025 Annual Report discloses the Mirena product family at EUR 1,366m (+12.5% cpa) and the YAZ family at EUR 700m (+10.7% cpa) and reports Lynkuet (elinzanetant) as a 2025 launch for menopause VMS; the UK first-worldwide approval (July 10, 2025) and US FDA approval (October 24, 2025) are corroborated by trade-press reporting. Limiting factor: Bayer no longer reports a consolidated 'Women's Healthcare' sub-segment total, so the aggregate franchise size is inferred from named product families rather than a single disclosed line, and Lynkuet revenue is not yet disclosed.
Materiality
disclosed — The issuer names specific women's-health product lines with revenue in the FY2025 Annual Report (Mirena family EUR 1,366m; YAZ family EUR 700m) and discloses the Lynkuet/elinzanetant launch, so the exposure is disclosed and quantifiable at the product-line level. The caveat is that Bayer discontinued a standalone consolidated 'Women's Healthcare' revenue line, so the total franchise figure (~EUR 2.07bn) is an aggregate of disclosed product families rather than a single disclosed number.
Financial evidence

Official public disclosures

Reference period: FY2025.

  • Group net salesEUR 45,575 million (-2.2% reported; +1.1% currency/portfolio-adjusted vs FY2024 EUR 46,606m)
    FY2025 (ended 31 Dec 2025)[1]
  • EBITDA before special itemsEUR 9,669 million (-4.5% vs FY2024 EUR 10,123m)
    FY2025[1]
  • EBIT (operating result, IFRS)EUR -1,077 million (operating loss)
    FY2025[1]
  • Net income / income after taxes (IFRS)EUR -3,620 million (net loss)
    FY2025[1]
  • Core EPS from continuing operationsEUR 4.91 (vs FY2024 EUR 5.05)
    FY2025[1]
  • Net cash provided by operating activitiesEUR 5,930 million (-19.5% vs FY2024 EUR 7,368m)
    FY2025[1]
  • Net financial debtEUR 29,843 million (-8.5% vs FY2024 EUR 32,626m)
    As of 31 Dec 2025[1]
  • Pharmaceuticals division salesEUR 17,829 million (+1.7% currency/portfolio-adjusted)
    FY2025[2]
  • Pharmaceuticals EBITDA before special itemsEUR 4,525 million (-4.2% vs FY2024 EUR 4,722m)
    FY2025[2]
  • Mirena product family sales (women's healthcare)EUR 1,366 million (+12.5% currency/portfolio-adjusted)
    FY2025[2]
  • YAZ product family sales (women's healthcare)EUR 700 million (+10.7% currency/portfolio-adjusted)
    FY2025[2]

Limitation: Figures are IFRS Group and divisional disclosures in EUR drawn directly from Bayer's official FY2025 Annual Report pages that were fetched this session. The FY2025 net result is a loss driven by litigation provisions and non-cash impairments, so headline profitability understates underlying operating performance (EBITDA before special items EUR 9,669m; positive core EPS EUR 4.91). Bayer does not publish a consolidated women's-healthcare franchise revenue line, so franchise sizing (~EUR 2.07bn) aggregates named product families (Mirena, YAZ) and excludes other women's-health products. Crop Science and Consumer Health segment detail and full balance-sheet line items were not separately fetched this session. Market-based valuation metrics (EV/EBITDA, P/E, market capitalization) require licensed market data and are not assessed.

Risks

Material risks and break conditions

Material risks

  • Glyphosate/Roundup litigation: a large US claim population and multi-billion settlement/provisioning create ongoing cash, provision-adequacy and headline risk, with additional legacy PCB litigation exposure; adverse verdict or appellate/preemption outcomes could force incremental charges.
  • Patent cliffs and biosimilar erosion: Xarelto loss of exclusivity and Eylea biosimilar competition are pressuring Pharmaceuticals revenue and require newer launches (Nubeqa, Kerendia, elinzanetant) to offset the decline.
  • High leverage against weak IFRS earnings: net financial debt of EUR 29,843m alongside an FY2025 net loss (EUR -3,620m) and reduced operating cash flow constrains financial flexibility (the dividend has already been cut) and elevates refinancing/rating sensitivity.
  • Women's-health-specific: Lynkuet enters a category where the first mover (Astellas Veozah) has under-performed commercially; menopause VMS is price-sensitive, and the contraception franchise faces reimbursement, pricing and generic/competitive pressure.
  • Macro and FX: reported Group sales fell 2.2% on currency headwinds despite currency/portfolio-adjusted growth, exposing euro-reported results to FX translation, alongside broad drug-pricing and regulatory pressure.

Thesis-break conditions

  • Lynkuet/elinzanetant fails to reach a material revenue run-rate within roughly two years of launch (mirroring Veozah's commercial struggle), undermining the menopause growth pillar.
  • The Mirena product family growth reverses into sustained year-over-year declines as US volumes roll over.
  • A material adverse litigation outcome forces incremental multi-billion-euro provisions or cash outflows exceeding operating cash flow, triggering portfolio divestitures that affect the women's-health/pharma franchise or a further capital-structure event.
Investability conclusion

Where the evidence lands

On the evidence gathered, Bayer presents as a diversified, cash-generative life-science platform with a genuine, issuer-disclosed and now-quantified women's-health franchise (Mirena family EUR 1,366m and YAZ family EUR 700m in FY2025) that it is extending into the non-hormonal menopause category via the newly approved Lynkuet (elinzanetant), first cleared in the UK (July 2025) and by the US FDA (October 2025). Analytically, the women's-health theme is a medium-weight, diversified contributor (~4.5% of Group sales) rather than a core earnings driver, within a group whose reported FY2025 results were an operating and net loss dominated by glyphosate litigation and roughly EUR 29.8bn of net financial debt. Theme exposure is real, disclosed and improving, but diluted; the case turns more on group-level litigation containment, pipeline execution and deleveraging than on the women's-health franchise in isolation. This profile describes the evidence and its limits and is not a recommendation to transact in the security.

Next diligence

  1. Track Lynkuet US script and revenue ramp quarter-by-quarter, plus the pending EU/EMA decision and other ex-US approval/reimbursement outcomes for elinzanetant.
  2. Quantify the Women's Healthcare franchise revenue, growth and margin (and any Bayer investor-day sizing) to firm up the theme's share of group sales and its profitability.
  3. Track the glyphosate/PCB litigation docket (verdict trends, appellate/preemption and any US Supreme Court developments) and assess provision adequacy against operating cash flow.
  4. Review the pharmaceutical loss-of-exclusivity schedule (Xarelto, Eylea) against the ramp of newer specialty products, plus Crop Science cost programs and impairment risk.
  5. Acquire licensed market data for valuation multiples and sell-side consensus, and obtain Crop Science / Consumer Health segment detail to complete the group picture.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Bayer Annual Report 2025 - Earnings Performance (Group net sales, EBITDA before special items, EBIT, net income, core EPS, operating cash flow, net financial debt)Bayer AG · primary · published 2026 · accessed 2026-07-22
  2. Bayer Annual Report 2025 - Pharmaceuticals division (segment sales, EBITDA, Mirena and YAZ product-family revenue, Lynkuet launch)Bayer AG · primary · published 2026 · accessed 2026-07-22
  3. Bayer AG equity listing - ISIN DE000BAY0017, WKN BAY001, symbol BAYN, Xetra FrankfurtDeutsche Boerse (Frankfurt Stock Exchange) · primary · published 2026-07-22 · accessed 2026-07-22
  4. Bayer receives FDA approval for non-hormonal menopause therapy Lynkuet (elinzanetant)BioPharma Dive · secondary · published 2025-10-27 · accessed 2026-07-22
  5. Bayer's elinzanetant (Lynkuet) receives first worldwide approval (UK MHRA) for menopause vasomotor symptomsWorld Pharmaceuticals · secondary · published 2025-07-11 · accessed 2026-07-22